Published in Healthcare Mergers, Acquisitions and Ventures Week, April 8th, 2006
The plan provides for the continuation of Able's business in order for it to complete its ongoing recall of products and other measures required by the U.S. Food and Drug Administration (FDA), for it to assist other government agencies with inquiries regarding Able's prior operations and to sell any remaining assets and wind down its operations.
Under the proposed plan, claims secured by collateral or rights of setoff and claims entitled to priority in payment will...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week